For people with diabetes, the increased risk of cardiovascular disease is an unfortunate reality. This includes atherosclerosis, a condition where the walls of the artery thicken due to accumulating fatty deposits, which can lead to heart attack and stroke.
"Heart disease is a major cause of death for both type 1 and type 2 [diabetes]," says George King, M.D., Chief Scientific Officer and Director of Research at Joslin. A team of researchers at Joslin led by Dr. King is one step closer to finding a solution for this insidious problem.
It is known that diabetic episodes of hyperglycemia and elevated levels of fatty acids cause the body to produce excessive amounts of PKC beta, an enzyme that plays a number of biological roles and has been shown to affect the cardiovascular system.
To study the link between PKC beta and atherosclerosis, scientists compared two groups of mice that were bred without the ability to produce apoliprotein E, a lipoprotein that removes cholesterol and lipids from the blood stream, giving them an innate tendency to develop atherosclerosis. One of these two groups was also bred to produce excessive levels of PKC beta in the endothelium. Both groups were fed a high fat, Western diet for twelve weeks after which researchers assessed their cardiovascular health.
The mice all gained weight at the same rate and had comparable blood pressures, cholesterol, and triglyceride rates. However, the group of mice that had elevated PKC beta experienced drastically higher rates of atherosclerosis. Joslin researchers learned that PKC beta inhibits the body's natural anti-atherogenic responses, which normally prevent fatty deposits from building up in blood vessels. As a result, the amount of aortic plaque in the PKC beta mice was twice that of control mice and their aortic atherosclerotic lesions were 1.7 times larger. Their endothelial walls also displayed signs of increased infection and inflammation.
Researchers believe that this greater instance of cardiovascular disease occurs partly because PKC beta indirectly inhibits the production of the anti-atherogenic, nitric oxide. Nitric oxide is vital to cardiovascular health, reducing the work the heart has to perform to pump blood and lowering the heart rate. In fact, lowered levels of nitric oxide are an early indicator of cardiovascular disease.
Now that excessive PKC beta has been shown to exacerbate atherosclerosis, researchers are hopeful that they will find better ways to manage cardiovascular disease in diabetic patients.
"If we could come up with a treatment for decreasing PKC beta, it may decrease the risk of cardiovascular disease in both Type 1 and Type 2 diabetes," says Dr. King.
About Joslin Diabetes Center
Joslin Diabetes Center, located in Boston, Massachusetts, is the world's largest diabetes research and clinical care organization. Joslin is dedicated to ensuring that people with diabetes live long, healthy lives and offers real hope and progress toward diabetes prevention and a cure. Joslin is an independent, nonprofit institution affiliated with Harvard Medical School.
Our mission is to prevent, treat and cure diabetes. Our vision is a world free of diabetes and its complications. For more information, visit http://www.joslin.org.
About Joslin Research
Joslin Research comprises the most comprehensive and productive effort in diabetes research under one roof anywhere in the world. With 30-plus faculty-level investigators and an annual research budget of $36 million, Joslin researchers focus on unraveling the biological, biochemical and genetic processes that underlie the development of type 1 and type 2 diabetes and related complications.
Joslin research is highly innovative and imaginative, employing the newest tools in genetics, genomics and proteomics to identify abnormalities that may play a role in the development of diabetes and its complications. Joslin Clinic patients, and others with diabetes, have the option of participating in clinical trials at Joslin to help translate basic research into treatment innovations.
Joslin has one of the largest diabetes training programs in the world, educating 150 M.D. and Ph.D. researchers each year, many of whom go on to head diabetes initiatives at leading institutions all over the globe.
Jeffrey Bright | EurekAlert!
Speed data for the brain’s navigation system
06.12.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)
Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
06.12.2016 | Power and Electrical Engineering
06.12.2016 | Earth Sciences
06.12.2016 | Physics and Astronomy